Once a treatment is submitted, UKRI collates evidence and data on the compound. This information is provided by:
- industry experts
- published literature
- other independent sources.
A team of due diligence managers validates the information and develops a briefing document for the relevant UK-CTAP sub-panel.
The sub-panels consider the briefs and provide advice on the treatments to either:
- COVID-19 Prophylaxis Oversight Group (POG), for treatments related to prophylaxis.
UK-CTAP and POG meet to consider the advice, briefs and any other information on the treatments. This group then makes a recommendation to CMO England and the principal investigators for each trial.
CMO England and the principal investigators then decide which treatments are entered into clinical trials.
For information on trial results, see: